Noxopharm Says US Biotechnology Company Finds 'Encouraging' Sofra Results; Shares Up 9%
MT Newswires Live
Aug 05, 2025
Noxopharm (ASX:NOX) said US-based Tezcat Biosciences found "encouraging" results in its pre-clinical in vitro studies of assets from the Sofra technology platform, according to a Tuesday filing with the Australian bourse.
Tezcat Biosciences conducted a series of studies, which demonstrated that the company's oligonucleotides can be attached to Tezcat's delivery system to create a new drug candidate with strong anti-inflammatory activity, the filing said.
The company has partnered with Tezcat since 2024, and plans are underway to undertake further studies in animal models, per the filing.
Noxopharm shares rose 9% in afternoon trade on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.